Evrysdi

EvrysdiEvrysdi™ (risdiplam), is the third treatment approved for SMA in Europe. It is an orally-available compound developed in collaboration with the SMA Foundation and PTC Therapeutics and which is used to increase the amount of SMN protein made by the SMN2 gene.

More information